Tirzepatide, the same active ingredient in Mounjaro®, represents the latest and most potent GLP-1 class medication for sustained weight loss. Patients have experienced an impressive average weight reduction of 24.3% over 72 weeks, in conjunction with a calorie-restricted diet and heightened physical activity. This dual-action GLP-1/GIP is for individuals with obesity (BMI ≥30) or overweight (BMI ≥27) accompanied by a weight-related condition, alongside dietary and exercise modifications.

Same active ingredient as Mounjaro®  

Dosage and Eligbility Information

This product adheres to a titration schedule. All patients must begin with the ‘Month 1’ dose. Subsequently, the dosage per injection gradually increases in Months 2, and 3. Finally, the maintenance dose (Month 4) can continue monthly based on your goals and healthcare provider approval. Below is the typical titration schedule for this product:

Month 1: 2.5 mg weekly

‍‍Month 2: 5.0 mg weekly

‍Month 3: 7.5 mg weekly

‍Month 4 & Beyond: 10 mg weekly

*Higher doses (12.5mg weekly and 15mg weekly) are available but aren't always recommended or necessary and do require medical approval.  If prescribed they will come at an additional cost of $150 per month.

Each monthly dosage provides medication needed for 4 weekly injections including syringes and alcohol pads. Please note that this is not medical advice. Every patient is unique, and this is just an example of what physicians could prescribe, if medically approved.